Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F4ZSM
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,499
Award facts
- Contract value 100% obligated
- $13,498.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,498.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 15, 2026, with an ultimate completion date of January 16, 2026. This is a non-set-aside award issued under open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2031, which serves as the primary vehicle enabling comprehensive pharmaceutical and medical supply deliveries to support military healthcare programs globally.
This delivery order represents a routine transaction under the larger DLA pharmaceutical supply chain infrastructure, demonstrating AmerisourceBergen's ongoing capability to fulfill federal medical supply requirements for specialty medications and therapeutic treatments. RINVOQ ER (upadacitinib) is a prescription medication used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in supplying both specialty and brand-name pharmaceuticals to military treatment facilities and veteran healthcare programs. The efficient completion timeline (one-day delivery order window) and firm fixed-price structure are consistent with AmerisourceBergen's established pattern of competitively awarded federal contracts across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F4ZSM?
SPE2DR26F4ZSM was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26F4ZSM worth?
The government has obligated $13,499 on SPE2DR26F4ZSM.
Is contract SPE2DR26F4ZSM an order under another contract?
Yes. SPE2DR26F4ZSM is a delivery order under SPE2DR25D2010, an indefinite delivery contract.
Was contract SPE2DR26F4ZSM competed?
The extent of competition for SPE2DR26F4ZSM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award